News

Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.

Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.

A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.

Researchers in China studied 168 patients over three 3 to determine the benefits of tyrosine kinase inhibitor therapy in patient s with ALK-positive locally advanced or metastatic NSCLC.

This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.

Researchers at the University of Michigan applied criteria regarding gene variants that may predispose patients to cancer to determine the proportion of veterans who would benefit from genetic counseling.

A recent systematic review found that the overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies.

Short-term radiotherapy with preoperative chemotherapy followed by surgery may be efficacious with acceptable toxicity and could be used as an alternative to chemoradiotherapy among patients with locally advanced rectal cancer.

Findings from a recent study show that many oncologists have not incorporated geriatric assessment tools because of perceptions that standardized geriatric assessments are difficult to implement or do not add any value.

Multiple factors were associated with shorter time to next treatment or overall survival in a recent retrospective real-world analysis on patients with ovarian cancer.